

All influenza vaccines marketed in the UK for the 2025 to 2026 season

Updated 6 June 2025

Supplier	Product	Vaccine type ¹	Age indications	Ovalbumin content micrograms/dose	Contact details
AstraZeneca UK Ltd	Fluenz®	LAIV (live attenuated influenza vaccine) supplied as nasal spray suspension, egg-cultured	From 24 months to less than 18 years of age	Less than 0.024 micrograms per 0.2 ml dose	0845 139 0000
Sanofi	Vaxigrip	Inactivated influenza vaccine, split virion, egg cultured	From 6 months	Equal to or less than 0.05 micrograms per 0.5 ml dose	0800 854 430
Viartis	Influvac® sub-unit TIV ▼	Inactivated influenza vaccine, surface antigen, egg cultured	From 6 months	Equal to or less than 0.1 micrograms per 0.5 ml dose	0800 358 7468
CSL Seqirus UK	Cell-based Trivalent Influenza Vaccine Seqirus ▼	Inactivated influenza vaccine surface antigen, cell cultured	From 6 months	Egg-free	0345 0093 804
Sanofi	Supemtek TIVr ▼	Inactivated influenza vaccine, recombinant, cell cultured	From 18 years	None	0800 854 430
Sanofi	Efluelda TIV-HD ▼	Inactivated influenza vaccine, split virion, 60 micrograms HA/strain, egg cultured	From 60 years	Equal to or less than 1 microgram per 0.5ml dose	0800 854 430
CSL Seqirus UK	Adjuvanted Trivalent Influenza Vaccine Seqirus ▼	Inactivated influenza vaccine surface antigen, adjuvanted with MF59C.1, egg cultured	From 50 years	Equal to or less than 1 microgram per 0.5ml dose	0345 0093 804

¹ All vaccines marketed for the 2025 to 2026 season are trivalent.